ChromaDex Corp. - FORM 10-Q - EX-32.1 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES?OXLEY ACT OF 2002) - November 12, 2015

Attached files

file filename
EX-10.1 - EXCLUSIVE SUPPLY AGREEMENT, EFFECTIVE AS OF AUGUST 27, 2015 BETWEEN HEALTHSPAN RESEARCH, LLC. AND CHROMADEX, INC. - ChromaDex Corp.ex10-1.htm
EX-31.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO ?240.13A?14 OR ?240.15D?14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED - ChromaDex Corp.ex31-2.htm
EX-10.4 - TAKE OR PAY PURCHASE AGREEMENT FOR NICOTINAMIDE RIBOSIDE CHLORIDE, EFFECTIVE AS OF SEPTEMBER 21, 2015, BETWEEN W.R. GRACE & CO. CONN. AND CHROMADEX, INC. - ChromaDex Corp.ex10-4.htm
EX-10.3 - INTEREST PURCHASE AGREEMENT, EFFECTIVE AS OF AUGUST 27, 2015 BETWEEN HEALTHSPAN RESEARCH LLC AND CHROMADEX, INC. - ChromaDex Corp.ex10-3.htm
EX-10.5 - SUPPLY AGREEMENT, EFFECTIVE AS OF AUGUST 28, 2015 AND FIRST ADDENDUM TO SUPPLY AGREEMENT, EFFECTIVE AS OF SEPTEMBER 30, 2015 BETWEEN NECTAR7 LLC AND CHROMADEX, INC. - ChromaDex Corp.ex10-5.htm
EX-10.2 - LIMITED LIABILITY COMPANY AGREEMENT, EFFECTIVE AS OF AUGUST 27, 2015 BETWEEN HEALTHSPAN RESEARCH LLC AND CHROMADEX, INC. - ChromaDex Corp.ex10-2.htm
10-Q - FORM 10-Q - ChromaDex Corp.cdxc10q_oct032015.htm
EX-31.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO ?240.13A?14 OR ?240.15D?14 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED - ChromaDex Corp.ex31-1.htm
Exhibit 32.1

Certification Pursuant to 18 U.S.C. Section 1350
(as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)

In connection with this quarterly report of ChromaDex Corporation (the “Company”) on Form 10−Q for the quarter ended October 3, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Frank L. Jaksch Jr., Chief Executive Officer of the Company, and Thomas C. Varvaro, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002, that, to our knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
 
2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: November 12, 2015
/s/ FRANK L. JAKSCH JR.
Frank L. Jaksch Jr.
Chief Executive Officer

/s/ THOMAS C. VARVARO
Thomas C. Varvaro
Chief Financial Officer

ChromaDex Corp. Reports

Also read